Biomarkers in spondyloarthritis

被引：12

作者：

Maksymowych W.P. ^{[1
]}

机构：

[1] Department of Medicine, University of Alberta, 562 Heritage Medical Research Building, Edmonton

来源：

Current Rheumatology Reports | 2010年 / 12卷 / 5期

关键词：

Ankylosing spondylitis; Biomarkers; Disease activity; Prognostic factors; Spondyloarthritis;

D O I：

10.1007/s11926-010-0127-9

中图分类号：

学科分类号：

摘要：

Key challenges in the management of spondyloarthritis focus on the lack of availability of measures of disease activity and the inability to predict joint damage or response to treatment, which is expensive and associated with potentially serious toxicity. Recent studies have focused on the possible contribution of soluble biomarkers, which have been selected based on current understanding of their role in inflammation and/or their association with turnover of joint matrix. Emerging candidates for disease activity markers include interleukin-6 and soluble cytotoxic T lymphocyte associated molecule-4. Potential predictors of damage include metalloproteinase-3 and sclerostin. Acute-phase reactants Creactive protein and serum amyloid A and interleukin-6 are currently the best predictors of treatment response. Significant study limitations are small sample size and the lack of multivariate analyses that can determine whether the biomarker contributes information that is independent of other clinical and laboratory variables used in routine care. © Springer Science+Business Media, LLC 2010.

引用

页码：318 / 324

页数：6

共 50 条

[1]

Van Der Heijde D.M., Wanders A., Mielants H., Et al., Prediction of progression of radiographic damage over 4 years in patients with ankylosing spondylitis [abstract], Ann Rheum Dis, 63, (2004)

[2]

Maksymowych W.P., Chiowchanwisawakit P., Clare T., Et al., Inflammatory lesions of the spine on MRI predict the development of new syndesmophytes in ankylosing spondylitis: Evidence for coupling between inflammation and ankylosis, Arthritis Rheum, 60, pp. 93-102, (2009)

[3]

Rudwaleit M., Claudepierre P., Wordsworth P., Et al., Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis, J Rheumatol, 36, pp. 801-808, (2009)

[4]

Rudwaleit M., Listing J., Brandt J., Et al., Prediction of a major clinical response (BASDAI 50) to tumor necrosis factor a blockers in ankylosing spondylitis, Ann Rheum Dis, 63, pp. 665-670, (2004)

[5]

Rudwaleit M., Schwarzlose S., Hilgert E.S., Et al., MRI in predicting a major clinical response to anti-tumor necrosis factor treatment in ankylosing spondylitis, Ann Rheum Dis, 67, pp. 1276-1281, (2008)

[6]

Van Der Heijde D., Kivitz A., Schiff M.H., Et al., Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 54, pp. 2136-2146, (2006)

[7]

Bollow M., Fischer T., Reisshauer H., Et al., Quantitative analyses of sacroiliac biopsies in spondylarthropathies: T cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancement detected by magnetic resonance imaging, Ann Rheum Dis, 59, pp. 135-140, (2000)

[8]

Appel H., Loddenkemper C., Grozdanovic Z., Et al., Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis, Arthritis Res Ther, 8, (2006)

[9]

Rgw L., Salonen D., Rahman P., Et al., Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis, Arthritis Rheum, 56, pp. 4005-4014, (2007)

[10]

Jung S.Y., Park M.C., Park Y.B., Lee S.K., Serum amyloid a as a useful indicator of disease activity in patients with ankylosing spondylitis, Yonsei Med J, 48, pp. 218-224, (2007)

← 1 2 3 4 5 →